In an interview with The Center for Biosimilars®, Angus Worthing, MD, FACP, FACR, chair of the American College of Rheumatology (ACR) Government Affairs Committee, explained the next steps for ACR after submitting a comment letter to HHS on reimbursement for Part B drug costs and prior authorizations.
Last month, the American College of Rheumatology (ACR) submitted a letter to HHS applauding CMS’ decision to assign unique J-codes to biosimilars and calling on CMS to address policies regarding prior authorizations. The letter also urged leaders to reverse a decision to adjust providers’ reimbursement for Part B drug costs based on physician performance under the Merit-Based Incentive Payment System (MIPS).
When asked if he thinks CMS will be responsive to the suggestions provided in the letter, Angus Worthing, MD, FACP, FACR, chair of ACRs Government Affairs Committee, told The Center for Biosimilars® in an email that ACR plans to meet with new HHS staff in the upcoming months in order to work collaboratively to address any barriers that may limit the ability of patients with arthritis or other rheumatic diseases to obtain care.
“The agencies have put out many requests for information lately,” said Worthing. “We take this as a positive, because we have the opportunity to voice our concerns, suggestions and praise, ultimately aiding in making our members’ voices heard.”
Overall, Worthing says, CMS had been responsive on all issues addressed in ACR’s letter. He feels that, as far as biosimilars are concerned, the government has listened to ACR’s suggestions, and he believes that it will continue to track this issue and support the continued implementation of policies to encourage biosimilar use.
In regard to adjusting providers’ reimbursement for Part B drug costs—based MIPS performance, Worthing felt that HHS had been receptive to suggestions: “They cite being bound by statue to interpret the law as they have. I believe they are listening and willing to work with Congress [and] physicians on this. From our Hill meetings with committee staff, we know that they have been talking to CMS about this issue to find the best solution possible, and we are hopeful this issue will be fixed in the Medicare Extenders package.”
Worthing said that ACR has already met with CMS' principal deputy administrator, Demetrios Kouzoukas, to discuss the current prior authorization process, which ACR says wastes time and resources, with a follow up meeting scheduled for February 5. “CMS staff have been engaged and interested in learning more about these issues from providers and patients. It appears the rule-making process or issued guidance are very palatable to CMS at this time. ACR and allied groups are working hard with CMS on these issues and will continue to do so,” said Worthing.
The next step for ACR is to continue to raise awareness of its cause: “With Part B, if this issue is not fixed, ACR will continue to meet with Hill staff and CMS to advocate for changing this policy. On all these topics, ACR will continue to submit comments to regulatory agencies when applicable and meet with the agencies relevant staff…we will continue to educate state legislators and support state legislation that aligns with our priorities,” said Worthing.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.